Is conventional antiplatelet therapy for the prevention of coronary stent thrombosis always safe? A case report of a patient with polycythemia vera

Dennis Zavalloni; Federica Marsico; Francesco Milone; Patrizia Presbitero

Is conventional antiplatelet therapy for the prevention of coronary stent thrombosis always safe? A case report of a patient with polycythemia vera

Ital Heart J. 2004 Feb;5(2):163-6.

Authors

Dennis Zavalloni¹, Federica Marsico, Francesco Milone, Patrizia Presbitero

Affiliation

¹ Division of Interventional Cardiology, Istituto Clinico Humanitas, Rozzano (MI), Italy.

PMID: 15086149

Abstract

A 63-year-old male patient with both polycythemia vera and unstable angina underwent an angioplasty with the deployment of a stent. Conventional antiplatelet therapy failed to prevent stent thrombosis and an association with chronic anticoagulation seemed to be the only safe treatment. Moreover, after the late withdrawal of warfarin, stent thrombosis recurred.

Publication types

Case Reports

MeSH terms

Abciximab
Angioplasty, Balloon, Coronary
Antibodies, Monoclonal / therapeutic use
Blood Vessel Prosthesis Implantation
Combined Modality Therapy
Coronary Angiography
Coronary Stenosis / diagnosis
Coronary Stenosis / therapy
Coronary Thrombosis / diagnosis
Coronary Thrombosis / prevention & control*
Echocardiography
Humans
Immunoglobulin Fab Fragments / therapeutic use
Male
Middle Aged
Platelet Aggregation Inhibitors / therapeutic use*
Polycythemia Vera / diagnosis
Polycythemia Vera / therapy*
Stents*

Substances

Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Abciximab